Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring

Fred Saad*, Cora N. Sternberg, Eleni Efstathiou, Karim Fizazi, Katharina Modelska, Xun Lin, Jennifer Sugg, Joyce Steinberg, Bettina Noerby, Neal D. Shore, Maha Hussain

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

While the majority of enzalutamide-treated patients with nonmetastatic castration-resistant prostate cancer in PROSPER had some increase from nadir in prostate-specific antigen at the time of radiographic progression, the median absolute increase was less than the Prostate Cancer Working Group 2 threshold of 2 ng/mL.

Original languageEnglish (US)
Pages (from-to)847-853
Number of pages7
JournalEuropean urology
Volume78
Issue number6
DOIs
StatePublished - Dec 2020

Keywords

  • Enzalutamide
  • Nonmetastatic castration-resistant prostate cancer
  • Prostate Cancer Working Group 2
  • Prostate-specific antigen progression

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring'. Together they form a unique fingerprint.

Cite this